ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 131 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $328 | -47.8% | 29,364 | 0.0% | 0.02% | -44.4% |
| Q2 2023 | $628 | -9.8% | 29,364 | +70.7% | 0.03% | -18.2% |
| Q1 2023 | $696 | -9.3% | 17,204 | +4.4% | 0.03% | -21.4% |
| Q4 2022 | $767 | -99.9% | 16,480 | -29.9% | 0.04% | -43.2% |
| Q3 2022 | $1,219,000 | -11.2% | 23,510 | -19.0% | 0.07% | -28.2% |
| Q2 2022 | $1,372,000 | +4.4% | 29,020 | +57.2% | 0.10% | +19.8% |
| Q1 2022 | $1,314,000 | +371.0% | 18,460 | +457.9% | 0.09% | -16.5% |
| Q2 2019 | $279,000 | -77.9% | 3,309 | -74.9% | 0.10% | -85.7% |
| Q1 2019 | $1,260,000 | -20.8% | 13,186 | -41.3% | 0.72% | +62.2% |
| Q4 2018 | $1,591,000 | +3.9% | 22,465 | +25.3% | 0.44% | +34.5% |
| Q3 2018 | $1,532,000 | +83.0% | 17,922 | +148.2% | 0.33% | +89.7% |
| Q2 2018 | $837,000 | +46.3% | 7,220 | +2.1% | 0.17% | +56.8% |
| Q1 2018 | $572,000 | – | 7,070 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |